Novel and Innovative Approach of Nanotechnology with their Applications in the Management of Infectious Disease, Tuberculosis : An Overview
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
Tuberculosis (TB) is considered a significant health problem caused by Mycobacterium tuberculosis. It is one of the second-deadly infectious diseases right after AIDS. Several factors such as poor patient compliance, high dose intake, low drug bioavailability and prolonged treatment of disease are responsible for the prevalence of multi-drug resistance tuberculosis and extensively drug-resistant tuberculosis cases. Therefore, developing such drug-resistant bacterial strains has created a robust and efficient system that can improve the therapeutic effectiveness of anti-tubercular drugs. This review manuscript highlights the therapeutic outcomes of a nanotechnology-based drug delivery system in treating TB. Various novel nanoformulations for anti-mycobacterial drugs have been explored. Such novel approaches would have shown several advantages such as sustained/controlled drug release, reduced dose frequency, and resolved poor patient compliance over many free anti-tubercular drugs. This framework will provide valuable information on various nanoparticle-based technology employed in treating TB infectious disease. Patent data were searched in google patent and nanoformulations outcomes for TB management improves health of patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Recent patents on nanotechnology - 18(2024), 2 vom: 08., Seite 140-163 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Singh, Sonia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antitubercular Agents |
|---|
| Anmerkungen: |
Date Completed 11.01.2024 Date Revised 26.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1872210516666220523122724 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM341390461 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM341390461 | ||
| 003 | DE-627 | ||
| 005 | 20240426233031.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1872210516666220523122724 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1388.xml |
| 035 | |a (DE-627)NLM341390461 | ||
| 035 | |a (NLM)35616678 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Singh, Sonia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Novel and Innovative Approach of Nanotechnology with their Applications in the Management of Infectious Disease, Tuberculosis |b An Overview |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.01.2024 | ||
| 500 | |a Date Revised 26.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a Tuberculosis (TB) is considered a significant health problem caused by Mycobacterium tuberculosis. It is one of the second-deadly infectious diseases right after AIDS. Several factors such as poor patient compliance, high dose intake, low drug bioavailability and prolonged treatment of disease are responsible for the prevalence of multi-drug resistance tuberculosis and extensively drug-resistant tuberculosis cases. Therefore, developing such drug-resistant bacterial strains has created a robust and efficient system that can improve the therapeutic effectiveness of anti-tubercular drugs. This review manuscript highlights the therapeutic outcomes of a nanotechnology-based drug delivery system in treating TB. Various novel nanoformulations for anti-mycobacterial drugs have been explored. Such novel approaches would have shown several advantages such as sustained/controlled drug release, reduced dose frequency, and resolved poor patient compliance over many free anti-tubercular drugs. This framework will provide valuable information on various nanoparticle-based technology employed in treating TB infectious disease. Patent data were searched in google patent and nanoformulations outcomes for TB management improves health of patients | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Mycobacterium tuberculosis | |
| 650 | 4 | |a Nanotechnology | |
| 650 | 4 | |a controlled release | |
| 650 | 4 | |a nanoparticles. | |
| 650 | 4 | |a sustained-release | |
| 650 | 4 | |a tuberculosis | |
| 650 | 7 | |a Antitubercular Agents |2 NLM | |
| 700 | 1 | |a Ahuja, Ashima |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Recent patents on nanotechnology |d 2007 |g 18(2024), 2 vom: 08., Seite 140-163 |w (DE-627)NLM185115284 |x 2212-4020 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2024 |g number:2 |g day:08 |g pages:140-163 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1872210516666220523122724 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2024 |e 2 |b 08 |h 140-163 | ||